Announcements

  • All
  • Announcements 2009
  • Announcements 2010
  • Announcements 2011
  • Announcements 2012
  • Announcements 2017
  • Announcements 2018
  • Announcements 2019
  • Announcements 2020
  • Announcements 2021
  • Announcements 2022
  • Announcements 2024
  • Announcements 2026

Paiania, April 27, 2026 – Today, Lavipharm S.A. conducted its Annual Analyst Update in accordance with the Company’s Financial Calendar for 2026. The presentation took place at the Athens Stock Exchange and was organized by the Hellenic Fund and Asset Management Association. In his opening remarks,...

Flash Note: Annual Financial Results 2025 (Unaudited Financial Data) Strong EBITDA Growth of 48.9% and Significant Increase in Earnings Before Tax by 108,2% Paiania, March 19, 2026 - Lavipharm S.A. informs the investment community of the key financial figures for fiscal year 2025. Consolidated Sales from...

Paiania, 05 March 2026 - Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2026, as follows.. FINANCIAL CALENDAR 2026...

Peania, November 17, 2025 – Lavipharm S.A. informs the investment community of the Group’s key consolidated financial figures for the nine-month period of 2025. Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from continuing and discontinued operations increased by 11.2%, reaching €10.47 million compared...

Financial Results for the First Half of 2025 – Steady Growth Momentum Peania, September 18, 2025 – Lavipharm Group reports an increase in its consolidated sales during the First Half of 2025. Specifically, consolidated sales from continuing operations amounted to €31.0 million, compared to €29.3 million...

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) Increased by 32.4% Paiania, 15 May 2025 – Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortization (EBITDA) for the First Quarter of 2025 increased by 32.4%, amounting to EUR 3.77 million compared to EUR 2.85 million...

(Unaudited Financial Data) Significant Sales and EBITDA Growth – Strong increase in net profit   Paiania, 19 March 2025 - Lavipharm S.A. informs the investment community on the key financial figures for the fiscal year 2024, as well as the Group’s operational developments to date: Consolidated Sales from ongoing...

Paiania, 14 March 2025 – Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2025, as follows:   Wednesday, 19 March 2025 Flash Note on Financial Results of FY 2024 Thursday, 3 April 2025 Announcement of FY 2024 Financial Report Thursday, 24...

Paiania, 4 February 2025 – Lavipharm S.A., a Pharmaceutical, Chemical, and Cosmetic Products Commercial and Industrial Societe Anonyme (hereinafter the “Company”), announces, in accordance with the provisions of Article 19 of Regulation (EU) No. 596/2014 and following a relevant notification received, that on 3 February...